Leqembi (lecanemab-irmb) - Biogen, Eisai
A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease (clinicaltrials.gov) - Oct 9, 2026 - P=N/A | N=270 | Not yet recruiting | Sponsor: Eisai Inc. 
New trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
http://clinicaltrials.gov/ct2/show/NCT07864623
 
Oct 9, 2026
 
Prev Next